Mission Pharmacal

Mission Pharmacal

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Mission Pharmacal is a 75+ year old, privately held pharmaceutical company with a diversified business model spanning branded, generic, and contract manufacturing. It has built a strong commercial portfolio in specialty therapeutic areas, particularly women's health (prenatal vitamins), urology, and dermatology. The company's strategy leverages its manufacturing expertise and commercial team to develop, source, and deliver products, while also offering CDMO services to other pharmaceutical companies, positioning it as an integrated player in the mid-market pharmaceutical space.

Women's HealthUrologyDermatology

Technology Platform

Integrated pharmaceutical development and manufacturing platform for small molecules, specializing in formulation, analytical testing, and commercial-scale production of solid oral, topical, and liquid dosage forms.

Opportunities

Opportunities exist to leverage its commercial expertise in women's health, urology, and dermatology to in-license or acquire additional branded products.
The growing trend of pharmaceutical outsourcing presents a significant expansion opportunity for its Contract Development and Manufacturing (CDMO) business segment.

Risk Factors

Key risks include dependence on mature branded products facing competition, severe price erosion in the generic pharmaceuticals market, and client concentration or attrition risk in the CDMO business.
As a private company, access to large-scale capital for major investments may be limited.

Competitive Landscape

Mission Pharmacal competes in branded markets against large pharmaceutical companies and specialty pharma firms (e.g., in prenatal vitamins, dermatology). In generics, it faces intense competition from large generic manufacturers like Teva and Mylan. Its CDMO services compete with other contract manufacturers ranging from large global CDMOs to smaller niche players.